High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery
BackgroundBariatric surgery (BS) represents the most effective therapy for obesity class III, or class II with at least one weight-related comorbidity. However, some patients have insufficient weight loss or clinically relevant weight regain after a successful primary procedure. This study aimed to...
Main Authors: | Federica Vinciguerra, Luigi Piazza, Carla Di Stefano, Claudia Degano, Alfredo Pulvirenti, Roberto Baratta, Lucia Frittitta |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Nutrition |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2023.1183899/full |
Similar Items
-
Use of liraglutide after bariatric surgery: a 36-month follow-up in a real-world setting in Chile
by: María Magdalena Farías
Published: (2024-09-01) -
Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
by: Miguel A. Rubio-Herrera, et al.
Published: (2023-10-01) -
Effectiveness and tolerability of liraglutide for the management of weight regain following sleeve gastrectomy
by: Mohammad Jamal, et al.
Published: (2024-02-01) -
Comparison of the effects of liraglutide and sibutramine in obese patients
by: G. A. Matveev, et al.
Published: (2021-07-01) -
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
by: Rafael Tamayo-Trujillo, et al.
Published: (2024-04-01)